William G Wierda, MD, University of Texas MD Anderson Cancer Center
Articles by William G Wierda, MD, University of Texas MD Anderson Cancer Center
William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.
CLL: Prognostic Markers
ByWilliam G Wierda, MD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University An overview of prognostic models in chronic lymphocytic leukemia (CLL).
Prognostic Factors in Chronic Lymphocytic Leukemia
ByWilliam G Wierda, MD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University A discussion about prognostic factors in patients with newly diagnosed chronic lymphocytic leukemia (CLL).
Molecular Testing for Newly Diagnosed CLL
ByWilliam G Wierda, MD, University of Texas MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,Ehab Atallah, MD, Medical College of Wisconsin,Steven Coutre, MD, Stanford University Medical Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center,Jennifer Woyach, MD, Ohio State University Ehab Attallah, MD, provides an overview of molecular testing for patients with newly diagnosed chronic lymphocytic leukemia (CLL).
